This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Canadian Pharmaceutical Company Duchesnay Inc. Sets For International Expansion Following The US Approval Of Its Morning Sickness Medication Diclegis® By The FDA

BLAINVILLE, QC, April 9, 2013 /CNW Telbec/ - Following the US approval of its morning sickness medication Diclegis by the US Food and Drug Administration (FDA), the Canadian pharmaceutical company Duchesnay Inc. is proud to announce that this approval sets the obstetric medicine specialty company for international expansion.

Diclegis has been available in Canada under the trade name Diclectin® for more than 30 years as the only prescription drug specifically indicated and approved for the management of nausea and vomiting of pregnancy (NVP), also known as morning sickness. Diclegis® will be commercialized in the US by Duchesnay USA based in Rosemont, Pennsylvania. The FDA granted Pregnancy Category "A" status to Diclegis, which means the results of controlled studies have not shown an increased risk to an unborn baby during pregnancy.

"The US approval of the patented drug Diclegis,  (Diclectin in Canada) by the FDA represents an important milestone for Duchesnay as we plan for strategic expansion through international partnerships.  We will leverage our long-standing and prominent expertise as an obstetric medicine company to reach key markets in Europe, Asia-Pacific and Latin America, where millions of pregnant women could beneficiate from our health products," stated Éric Gervais, Executive Vice-president of Duchesnay Inc. 


Diclectin delayed-release combination of doxylamine succinate and pyridoxine hydrochloride is the only prescription antinauseant and antiemetic drug labeled and approved in Canada for use in pregnancy. Its long and outstanding track record of safety and efficacy has made Diclectin the drug of choice in Canada in the clinical guidelines of the Motherisk Program at the Hospital for Sick Children in Toronto and the Society of Obstetricians and Gynaecologists of Canada (SOGC). Diclectin has been used by over two million pregnant women in Canada.


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs